These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29064745)

  • 1. Timing of the interim analysis in adaptive enrichment designs.
    Benner L; Kieser M
    J Biopharm Stat; 2018; 28(4):622-632. PubMed ID: 29064745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On Enrichment Strategies for Biomarker Stratified Clinical Trials.
    Wang X; Zhou J; Wang T; George SL
    J Biopharm Stat; 2018; 28(2):292-308. PubMed ID: 28933670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal decision rules for biomarker-based subgroup selection for a targeted therapy in oncology.
    Krisam J; Kieser M
    Int J Mol Sci; 2015 May; 16(5):10354-75. PubMed ID: 25961947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.
    Li W; Chen C; Li X; Beckman RA
    Stat Med; 2017 May; 36(12):1843-1861. PubMed ID: 28303586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials.
    Zhang Z; Chen R; Soon G; Zhang H
    Stat Med; 2018 Jan; 37(1):1-11. PubMed ID: 28948633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Point estimation in adaptive enrichment designs.
    Kunzmann K; Benner L; Kieser M
    Stat Med; 2017 Nov; 36(25):3935-3947. PubMed ID: 28783881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flexible alpha allocation strategies for confirmatory adaptive enrichment clinical trials with a prespecified subgroup.
    Sugitani T; Posch M; Bretz F; Koenig F
    Stat Med; 2018 Oct; 37(24):3387-3402. PubMed ID: 29945304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blinded sample size recalculation in adaptive enrichment designs.
    Placzek M; Friede T
    Biom J; 2023 Feb; 65(2):e2000345. PubMed ID: 35983952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simple subgroup approximations to optimal treatment regimes from randomized clinical trial data.
    Foster JC; Taylor JM; Kaciroti N; Nan B
    Biostatistics; 2015 Apr; 16(2):368-82. PubMed ID: 25398774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multistage adaptive biomarker-directed targeted design for randomized clinical trials.
    Gao Z; Roy A; Tan M
    Contemp Clin Trials; 2015 May; 42():119-31. PubMed ID: 25778672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker threshold adaptive designs for survival endpoints.
    Diao G; Dong J; Zeng D; Ke C; Rong A; Ibrahim JG
    J Biopharm Stat; 2018; 28(6):1038-1054. PubMed ID: 29436940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
    Mehta C; Schäfer H; Daniel H; Irle S
    Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim treatment selection with a flexible selection margin in clinical trials.
    Wu Y; Zhao PL
    Stat Med; 2013 Jul; 32(15):2529-43. PubMed ID: 23212767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population enrichment designs: case study of a large multinational trial.
    Mehta CR; Gao P
    J Biopharm Stat; 2011 Jul; 21(4):831-45. PubMed ID: 21516572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sample size adjustment designs with time-to-event outcomes: A caution.
    Freidlin B; Korn EL
    Clin Trials; 2017 Dec; 14(6):597-604. PubMed ID: 28795844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility.
    Walter SD; Han H; Briel M; Guyatt GH
    Stat Med; 2017 Apr; 36(9):1506-1518. PubMed ID: 28183155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASIED: a Bayesian adaptive subgroup-identification enrichment design.
    Xu Y; Constantine F; Yuan Y; Pritchett YL
    J Biopharm Stat; 2020 Jul; 30(4):623-638. PubMed ID: 31782938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal Bayesian adaptive trials when treatment efficacy depends on biomarkers.
    Zhang Y; Trippa L; Parmigiani G
    Biometrics; 2016 Jun; 72(2):414-21. PubMed ID: 26575199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient recruitment strategies for adaptive enrichment designs with time-to-event endpoints.
    Uozumi R; Yada S; Kawaguchi A
    BMC Med Res Methodol; 2019 Jul; 19(1):159. PubMed ID: 31331277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptive seamless designs with interim treatment selection: a case study in oncology.
    Carreras M; Gutjahr G; Brannath W
    Stat Med; 2015 Apr; 34(8):1317-33. PubMed ID: 25640198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.